Symbiotec Pharmalab Limited (NSE:SYMBIOTEC)
India flag India · Delayed Price · Currency is INR
1,120.00
+41.75 (3.87%)
Last updated: Sep 7, 2026, 10:55 AM IST

Symbiotec Pharmalab Balance Sheet

Millions INR. Fiscal year is Apr - Mar.

Assets

Fiscal Year
FY 2026FY 2025FY 2024FY 2023FY 2022
Period Ending
Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Cash & Equivalents
100.4263.974.9545.5191.62
Short-Term Investments
0.850.790.688.733.78
Cash & Short-Term Investments
101.25264.6975.6354.2495.4
Cash Growth
-61.75%249.98%39.44%-43.15%-
Accounts Receivable
2,0011,7571,2571,1201,435
Other Receivables
114.64158.59140.16139.8458.04
Receivables
2,1161,9151,3971,2591,493
Inventory
2,3692,6153,3582,4382,457
Prepaid Expenses
52.9250.7450.9544.5957.26
Other Current Assets
216.8483.49200.76205.74152.28
Total Current Assets
4,8554,9295,0824,0024,255
Property, Plant & Equipment
11,4899,6976,1954,8073,184
Long-Term Investments
44.8414.535.1148.1954.05
Other Intangible Assets
--2.387.512.62
Other Long-Term Assets
1,4191,1561,6331,036646.3
Total Assets
17,80815,79712,9489,9008,152

Liabilities

Fiscal Year
FY 2026FY 2025FY 2024FY 2023FY 2022
Period Ending
Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Accounts Payable
1,383884.962,276879.7887.73
Accrued Expenses
196.22147.1129.51124.43167.7
Short-Term Debt
2,8752,284502.971,053635.88
Current Portion of Long-Term Debt
319.99595.0416.6663.36
Current Portion of Leases
10.258.775.47--
Current Income Taxes Payable
79.46110.0830.494.8820.34
Current Unearned Revenue
135.05358.15417.2171.153.96
Other Current Liabilities
276.39337.8133.68141.84118.01
Total Current Liabilities
5,2764,7263,5122,2811,887
Long-Term Debt
684.132,5301,9521,1207.31
Long-Term Leases
20.5126.4228.4420.7811.32
Long-Term Unearned Revenue
39.58----
Pension & Post-Retirement Benefits
168.839477.360.9255.76
Long-Term Deferred Tax Liabilities
58.13219.91199.44201.58204.47
Other Long-Term Liabilities
65.1953.0429.721.47-
Total Liabilities
6,3127,6495,7993,6852,166

Shareholders' Equity

Fiscal Year
FY 2026FY 2025FY 2024FY 2023FY 2022
Period Ending
Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Common Stock
125.47109.36109.36109.36109.36
Additional Paid-In Capital
3,9101,6111,6111,6111,611
Retained Earnings
7,5426,4465,4844,4954,266
Comprehensive Income & Other
-80.82-17.76-54.22--
Total Common Equity
11,4978,1497,1506,2155,987
Minority Interest
-1.4-1.89-2.05-0.92-1.09
Shareholders' Equity
11,4968,1477,1486,2145,986
Total Liabilities & Equity
17,80815,79712,9489,9008,152

Additional Metrics

Fiscal Year
FY 2026FY 2025FY 2024FY 2023FY 2022
Period Ending
Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Total Debt
3,9105,4442,5062,200657.87
Net Cash (Debt)
-3,809-5,180-2,430-2,145-562.47
Net Cash Growth
-----
Net Cash Per Share
-65.86-92.89-43.66-39.23-10.29
Filing Date Shares Outstanding
62.7354.6855.6654.6854.68
Total Common Shares Outstanding
62.7354.6855.6654.6854.68
Working Capital
-420.21202.61,5701,7212,368
Book Value Per Share
183.27149.02128.46113.66109.49
Tangible Book Value
11,4978,1497,1486,2085,974
Tangible Book Value Per Share
183.27149.02128.42113.53109.26
Land
103.55102.01101.01101.01101.01
Buildings
2,8091,3081,268979.51924.58
Machinery
10,4344,6054,3313,1312,915
Construction In Progress
644.815,6822,0831,821396.79